Caricamento...
Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
Trastuzumab deruxtecan (DS‐8201) is a human epidermal growth factor receptor 2 (HER2)–targeting antibody–drug conjugate with a novel enzyme‐cleavable linker, a topoisomerase I inhibitor payload, and a drug‐to‐antibody ratio of ≈ 8. We have characterized the population pharmacokinetics (PK) of trastu...
Salvato in:
| Pubblicato in: | Clin Pharmacol Ther |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8246728/ https://ncbi.nlm.nih.gov/pubmed/33118153 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.2096 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|